VBI Vaccines (NASDAQ:VBIV) Coverage Initiated at StockNews.com

StockNews.com initiated coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research report report published on Friday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

Shares of NASDAQ:VBIV opened at $0.02 on Friday. VBI Vaccines has a 52 week low of $0.06 and a 52 week high of $1.35. The company’s 50 day moving average is $0.49 and its two-hundred day moving average is $0.57.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.